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The emergence of multiple resistance to 0-lactam antimicrobial agents is a major problem in the treatment of patients 
infected with Enterobacteriaceae that characteristically produce inducible p-lactamases. Inducible and 'derepressed' AmpC 
p-lactamases are produced by Enterobacter spp., Citrobacter freundii, Serratia marcescens, Morganella morganii and 
Providencia spp. Resistance to broad-spectrum 0-lactams has emerged in 1644% of these strains from infections treated 
with one of the newer cephalosporins, even in combination with other antimicrobials. Multiply resistant organisms have 
spread widely both locally, within hospitals, and nationally. This trend has been shown to correlate closely with the extent 
of usage of some third-generation cephalosporins. These resistant strains, especially Enterobacter spp., are more regularly 
isolated from seriously ill patients (especially from respiratory sources), or in intensive care units and pose one of the 
greatest challenges to contemporary chemotherapy of infections in hospitalized patients. Zwitterionic fourth-generation 
cephalosporins combine the properties of rapid bacterial outer membrane penetration with high stability to AmpC 
p-lactamase with good affinity for the penicillin-binding proteins to achieve in vitro activity against AmpC-producing 
organisms, including the majority of strains highly resistant to ceftazidime and other earlier generation cephalosporins. 
These features have contributed to their clinical success in the therapy of infections caused by Enterobacter spp. with and 
without resistance to third-generation compounds. Other alternative agents for chemotherapy of infections due to AmpC 
P-lactamase-producing strains (inducible or derepressed expression) should also be considered e.g. carbapenems, 
aminoglycosides and fluoroquinolones. 
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I NTRO D UCTlO N 
The emergence of bacterial resistance to antimicrobial 
agents continues to represent an important clinical 
problem. In recent years, many classes of antimicrobials 
have become less effective as a result of evolving 
microbial resistance mechanisms. In some cases this 
has been linked to extensive use of selecting drugs [1,2]. 
In nosocomial infections, resistance continues to be a 
threat to contemporary antimicrobial chemotherapy. 
Current resistance problems among Gram-positive 
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bacteria include multidrug-resistant staphylococci, 
glycopeptide-resistant enterococci and penicillin- and 
multidrug-resistant pneumococci. Kesistance among 
Gram-negative bacteria is attributable to ceftazidime- 
resistant Bush Group 1 producing Enterobacteriaccae. 
extended-spectrum P-lactamases in Klebsiella spp., Proteus 
mirabilis and Escherichia coli, and multidrug resistance 
among Pseudomonm spp. The likelihood of encountering 
Stenotvophomonas maltoplzilia as a nosocomial pathogen 
is increasing [ 3 ] .  Fluoroquinolone resistance is also 
present and increasing in staphylococci, eiiteric bacilli 
and Aeudomonas spp. [3]. 
Although reduced outer membrane permeability and 
moddication of the penicihn binding proteins (PBPs) are 
among the most important niechanisms of bacterial 
resistance to p-lactam antimicrobial agents, P-lactamase 
production accounts for a major source of resistance [4]. 
Virtually all bacteria produce chromosomally-mediated 
P-lactamases and plasmid-mediated P-lactamases arc 
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widespread in Gram-negative bacteria. More recently, 
the plasmid-mediated, extended-spectrum p-lactamases 
have emerged as clinically important resistance 
determinants in the Enterobacteriaceae [4-6]. Metallo 
P-lactamases confer resistance to carbapenems and, 
although still uncommon at present, may pose a threat 
in the future [4]. 
The introduction of third-generation cephalosporins 
improved the effectiveness of therapy for the vast 
majority of infections caused by Gram-negative 
bacteria; however, the use of these highly p-lactamase 
stable compounds has led to the emergence of resistant 
species [2]. Bacteria that possess chromosornally- 
mediated Bush Group 1 P-lactamase have been 
implicated in the development of resistance and 
multiply-resistant, stably derepressed mutants have 
emerged during therapy [7,8]. 
Beta-lactamases are present in virtually all C Tram- 
negative bacilli. However, in some bacterial strains, 
such as E .  coli and Klebriella spp., the P-lactamase is 
produced at a low level and cannot be induced to greater 
production by the presence of p-lactams. In other 
species, p-lactamase production occurs at low levels, 
but is inducible when exposed to certain p-lactams, 
commonly resulting in resistance to these agents. 
These inducible p-lactamases are frequently found in 
Enterobacter spp., Citrobacter fveundii, Providencia spp., 
Motgunella spp. and Sewatia spp. (Table 1) [7,8). These 
organisms also routinely undergo spontaneous mutation 
to become constitutive p-lactamase producers. This, 
in turn, confers resistance to most p-lactams, including 
third-generation cephalosporins. However, p-lactam 
antimicrobial agents differ, not only in their sensitivity 
to these enzymes, but also in their ability to induce 
synthesis of the enzyme and selection of resistant, 
derepressed mutants [4,9]. 
Beta-lactamases are an enormously vaned class of 
enzymes, classified until recently both on the basis of 
their substrate hydrolytic spectrum and whether 
encoded by plasmid- or chromosomally-located genes 
[lo-121. However, such phenotypic classification 
schemes were found to be compromized in 
satisfactorily recognizing the point mutations which 
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could dramatically alter substrate specificity and inhibitor 
susceptibilities. Therefore, p-lactamases are increasingly 
classified at a molecular level on the basis of amino 
acid sequence [13], as originally proposed by Ambler 
[14]. Four classes are recognized under this scheme: 
classes A, C and D are serine active site enzymes, 
whereas class B metallo-enzymes require zinc for 
activity. Expressioii of p-lactaniase can be constitutive 
or inducible. Constitutive and non-induced enzyme 
levels are normally quite low; however, induction can 
lead to several hundred-fold increases in activity. 
Mutations in genetic control mechanisms can also result 
in derepression of the enzyme, whereby 0-lactamase 
production is maintained at a very high level. 
The genetics of induction are discussed below; 
however, it is important at this stage to define the 
terms ‘induction’ and ‘derepression’. ‘Induction’ is 
defined as the synthesis of enzyme-protein in direct 
response to induction by the substrate (inducer), a 
phenotypic, temporary response to an environmental 
change. ‘Derepression’, in contrast, is a constitutive, 
permanent feature of the mutant (stable genetic 
change) whereby large amounts of enzyme-protein 
are produced consistently. 
Ambler Class A p-lactamases, includmg the common 
plasmid-mediated TEM enzymes, are produced 
constitutively by K.  pneumoniae, Bacteroides fvagilis and 
inducibly by K .  oxytoca and Staphylococcus aureus. Class B 
metallo-enzymes are relatively uncommon and mainly 
produced by S .  maltophilia, Bacillus cereus and some 
strains of Bacteroides spp. Howeyer, the Class B enzymes 
have the important ability to rapidly hydrolyze those 
drugs generally stable to the other enzyme classes, such 
as the carbapenems and the cephamycins. 
AmpC P-lactamases are produced by many bacterial 
species. Production of inducible AmpC P-lactamases 
is limited to a group of organisms including 
Enterobacter spp., C. freundii, S. rnarcescens, M .  morganii, 
Providencia spp. and P. aeruginosa. These bacterial species 
are regularly isolated from hospitalized patients, 
including the seriously ill, and pose one of the greatest 
challenges to contemporary nosocomial or hospitalized 
patient infection chemotherapy [2,4,7,8,15]. 
Table 1 Enterobacteriaceae species often possessing inducible Bush Group I P-lactamases and associated with strains having 
resistance to so-called ‘third-generation’ cephalosporins 
Genus Species 
Enterobacter 
Citrobacter 
Serratin 
Morgariella 
Prouidrlzcia 
aerogenes, cloacae 
fveirndii 
marccscens 
rnorganii 
rettgeri, stuartii 
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Enterobacter spp. are increasing in clinical practice 
[3,16,17]. In a survey conducted in the USA in 1994, 
of > 8,500 organisms isolated from patients residing in 
43 medical centers, Enterobacter spp. were responsible 
for 6.3% of all infections 131. Entevobactev was found to 
be the fourth most prevalent genus in respiratory tract 
infections, accounting for 9.2% of infections (with 
S. marcescens accounting for a further 4.6% of infections). 
Of  the 3,224 organisms isolated from urinary tract 
infections, 4.7%) were Enterobacter spp. and 1.8% were 
C. fvectndii. Entevobactev was also a significant pathogen 
in skin and soft tissue infections, accounting for 6.8% 
of the total nuniber of isolates (with S .  marcescens 
responsible for another 2.4%). In blood stream infections, 
Entevobactev spp. accounted for 3.9% of the total. 
Similar data were obtained in the 1995196 SCOPE 
study, where Enterobactev spp. and S .  marcescens accounted 
for 5% and 2%, respectively, of nosocomial blood stream 
infections [16]. 
Enterobactev spp. was also found to be a significant 
pathogen isolated in Intensive Care Units (ICUs). I n  
the National Nosocomial Infections Surveillance 
system (NNIS) of ICU infections conducted in 1990, 
Entevobacter spp. was among the top five pathogens [ 171. 
In this study, the incidence per site of infection was: 
respiratory tract (5.3%), surgcal wound (10.3%)) and 
urinary tract (6.1%). These findings were confirmed by 
the results of a European study, where Enterobacter spp. 
accounted for 8%) of pathogens isolated fioni infections 
in medical ICUs, surgical ICUs and hematology/ 
oncology units [18]. 
GENETICS OF INDUCIBLE AmpC EXPRESSION IN 
ENTEROBACTERIACEAE 
Translation of the umpC gene is regulated by the ampR 
gene product, AmpR [19]. AmpR is a bifunctional 
protein, being a transcriptional activator in the presence 
of some p-lactams and a repressor in their absence. 
Deletion mutations of am$ generate a non-inducible 
phenotype, with AmpC being expressed at a level 
two- to three-fold higher than the normal, uninduced 
basal level [20,21]. 
At least two other genes, ampD and aw/pG, are 
involved in ArnpC induction. A third gene, ampE, 
was initially thought to be involved in p-lactamase 
expression, but recent work has shown that it is not 
required 1221. AmpD and ampG are present in all 
Enterobacteriaceae tested to date, even those lacking 
an inducible AmpC P-lactamase, suggesting other 
primary functions for AmpD and AmpG [23]. AmpD 
is, in fact, a cytosolic N-acetyl muraniyl-L-alanine 
amidase which participates in the intracellular recycling 
of peptidoglycan fragments [23.24]. DNA protection 
studies have failed to show binding to the regulatory 
region upstream from ampC, hence, it is unlikely that 
AmpD directly influences the expression of ampC. 
Null mutations in anipD cause derepresion, while other 
mutations generate a hyper-inducible phenotype, 
whereby lower levels of inducer are required to 
promote ampC expression. 
AnipG is believed to be a permease for a large 
muropeptide which might be a hypothetical activating 
ligand for P-lactamase induction [25]. In  the absence 
of t h s  protein no induction occurs, nor does constitutive 
activation of amPC take place i n  atnp6, ampD double 
mutants [26,27]. 
Several models have been proposed to show the 
interaction of the various genes and gene products 
involved in AmpC induction. New insights into the 
relationship between P-lactamase induction and 
peptidoglycan recycling have given rise to an alternative 
view of the Bennett and Chopra model 1281. This 
suggests that AmpR controls p-lactamase production 
by sensing the cytoplasmic level of niuropeptides, 
which is influenced by the activities of Amp13 and 
AInpG in peptidoglycan recycling and indicative of 
the presence or absence of p-lactam antimicrobials 
(Figure 1) [25,29,30]. Peptidoglycan recycling has a 
signalling role in p-Iactamase induction and derepression 
and is part of a communication link between the 
dynamic state of the cell wall, essential for growth and 
cell division, and the transcription niechanism of arnpC. 
RESISTANCE AMONG ENTERIC BACTERIAL SPECIES 
The clinical and epidemiological importance of 
inducible 0-lactamases and their stably derepressed 
mutants in Gram-negative hactcria has increased 
dramatically since the introduction of the third- 
generation cephalosporins [31]. 'These stably derepresscd 
mutants were present in significant nunibers among 
clinical isolates even before the clinical introduction of 
the third-generation cephalosporins. Occurrence rates 
of more than 10% for high P-lactamase-produciiig 
strains (derepressed AinpC) aniong Enterobactcriaceae 
were not uncommon between 1976 and 1981, although 
the incidence of such strains varied according to site 
of infection, geographical location and selective 
pressures [32]. In 1982, before the introduction of 
third-generation cephalosporins, E .  rhacae, C. f k r r z d i i  
and S. nzavcescens isolated from nicdical centcrs in tlic 
USA were all relatively susceptible to cefotaxime, with 
MIC,, values I 5 mg/L 1321. In contrast, data reported 
from Europe and the Far East showed that strains of 
C.  frecmdii and E .  cloacae were niorc resistant, with 
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Figure 1 Hypothetical model for control of the expression of inducible ampC genes in Gram-negative bacteria [24-26,29,30]. 
The proposed interconnected pathway for recycling muropeptides and for their involvement in P-lactamase induction is 
illustrated. 0 GlcNac; 6 anhMurNac; 0 MurNac; 0 Ala; + Glun; DAP. 
(A) The recycling pathway. As shown, murein is degraded by known enzymes in the periplasm to muramyl peptides. The 
muropeptide GlcNac-anhMurNac-tripeptide, tetrapeptide and pentapeptide are transported into the cytoplasm through 
AmpG. Disaccharides are cleaved by P-N-acetyl-glucosaminidase into monosaccharides. The muropeptides are then degraded 
into GlcNac-anhMurNac and free tripeptide, tetrapeptide or pentapeptide by AmpD. Free tripeptide can then be added 
directly to UDP- Nacetylmuramic acid by an as yet unidentified enzyme, thereby reintroducing it into the biosynthetic 
pathway for murein synthesis. 
Derepression can occur because of mutations in the ampD or ampR gene. The ampR mutations change the AmpR protein 
into an activator. The ampD mutations alter the AmpD protein to an inactive enzyme, which results in an accumulation of 
the muramyl peptides in the cytoplasm. 
(B) Muropeptides as inducers of P-lactamase. Intracellular accumulation of GlcNac-anhMurNac-tripeptide as a result of the 
presence of the P-lactam antibiotics or of anhMurNac-tripeptide as the result of inactivation of arnpD triggers production of 
C. jieundii AmpC P-lactamase. The muropeptides presumably bind to the transcriptional regulator AmpR and convert it into 
an activator for ampC expression. (C. freundii ampR and ampC are expressed from a plasmid.) 
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MIC,, values three- and 30-fold higher, respectively, 
clearly attributable to derepressed AmpC production 
(Table 2). Further reports [33-353 have also indicated 
that up to 40% of isolates (1987-91) had stably 
derepressed p-lactamases. 
Over the following decade, with increased use of 
broad-spectrum p-lactams, resistance levels rose 
markedly throughout the world in general such as 
Enterohacter and in C.freundii, although there continued 
to be regional and national differences. International 
variations in resistance to third-generation cephalosporins 
have been documented in a review of surveys between 
selected hospitals in five nations (USA, France, Germany, 
Italy and Japan) [36]. Cefotaxime, used as an index 
third-generation cephalosporin, had relatively high 
susceptibilities in Germany, where 80% and 100% of 
E .  cloacae and S .  marcescens were inhibited by 5 8mg/L. 
In contrast, high levels of resistance were observed in 
Japan and Italy, where only 57.7% of E .  cloacae (Japan) 
and 63.3% of S .  marcescens (Italy) were susceptible. 
High levels of resistance to the third-generation 
cephalosporins have also been reported from studies in 
the USA. In one report in 1993, using reference NCCLS 
tests and breakpoint criteria, only 6 6 4 2 %  of some 
Enterobactenaceae remained susceptible to cefotaxime 
[37]. In another US survey involving >30,000 enteric 
bacilli isolated during 1994, 18% of S. maycescens, 23% 
of C. freundii and 34% of E. cloacae were resistant to 
cefotaxime. These resistance levels have been confirmed 
by more recent surveillance data [36-381. Data from 
1994-1995, using two standardized methods, indicated 
that 21-4096 of E.  cloacae isolated from blood, lower 
respiratory tract, urinary tract and skin and soft tissue 
infections were resistant to cefiazidinie 13,381 (Table 3). 
In 1995, in a five-hospital study (>1,000 straidsite), 
2&30% of strains (depending on the species tested) were 
resistant to the third-generation cephalosporins [39]. 
Resistance levels have also increased in other areas 
of the world, although the incidence varies according 
to geographic location, the testing method and 
interpretation criteria used. In a Belgian study conducted 
in 1993, the susceptibility of 8,625 ICU and hematology 
patient isolates was examined. Of these, 30% of E.  cloacae 
and 41% of C.-fieundii strains were found to be resistant 
Table 2 Activity of cefotaximc against Bush Group 1 (Ambler class A) 0-lactamase-producing Enterobactcriaccae isolated 
prior to its widespread clinical usea 
~ ~~ ~ ~ 
MIC ( n ~ g / L ) ~  
Orgdimrn Collection source (no tested) MIC50 MICYO No of re6 cited 
Citrohacfwfieundii 
Enterohacter aerojicnrs 
Enterohactcr cloacae 
USA (48) 
World (88) 
USA (152) 
World (42) 
USA (153) 
World (245) 
0.1 1 
0.35 
0.12 
0.20 
0.12 
6.2 
5.0 
18.2 
1 .0 
6.3 
4 
8 
1.3 1 0  
37.0 
Scrtatia ma~ce.~cens USA (597) 0.47 5.2 25 
World (449) 0.82 5.2 
aModified from report of 15,672 entenc bacilli by Jones and Tbornsbeny [32]. 
bThe MIC,, and MIC,, are the lowest concentration inhibiting growth of 50% and 90% of tested strains, rmpectively. 
Table 3 Rates of resistance to third-generation cephalosporins (cefiazidime) among E.  ckiacae isolates reported in the USA in 
1994-1995 [3,38Ia 
% susceptible by infection siteb.' 
Monitored Blood 
centers (No.) 
LRTI UTI SSTI 
Jones et al. (1995) 43 60 66 74 71 
Baron and Jones (1995) 236 75 75 N D  79' 
allata derived from NCCLS standardized test (disk diffusion and broth microdilution). 
"Blood = bacteremias; LRTI = lower respiratory tract infections; UTI = urinary tract infections; SSTI = skin and soft tissue infections; 
N D  = Not determined. 
<Isolates from ititra-abdominal and gynaecology wound infections exhibited 74-76% susccptibility to ceftazidinie. 
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to third-generation cephalosporins [18], data very similar 
to those reported in North America. 
T h e  inc rease  i n  r e s i s t ance  a m o n g s t  
Enterobacteriaceae has been correlated with an 
increase in the use of broad-spectrum antimicrobial 
agents. For example, resistance amongst E. cloacae to 
ceftazidime has been shown to be directly related to 
the use of cefiazidime (Figure 2) [2]. As the use of 
ceftazidime increased steadily, the susceptibility to 
cefiazidime declined (p < 0.02). To examine temporal 
trends in ceftazidime resistance, susceptibility data 
reported to the NNIS survey (CDC) during 1987-1991 
were analyzed among nosocomial Enterobactev spp., 
K. pneumoniae and P. aeruginosa. Progressive increases 
in resistance were observed for Enterobactev spp. and 
K. pneumoniae over time, with the percentage of resistant 
strains of Enterobactev spp. increasing significantly during 
1989-1991 [35]. The increase in cefiazidime resistance 
in K. pneumoniae was related to plasmid-mediated 
extended spectrum 0-lactamases [4-6,12,13]. 
h 
>. c 
El 3 
70 8 
5 
I k 0 . 0 2  
50' I 
0 2 4 6 8 
Ceftazidime use (g/quarter/bed) 
Resistance to third-generation agents caused by 
derepressed species appears to be greatest amongst the 
most seriously ill patients, such as those in the ICU 
setting [40]. Furthermore, E. cloacae consistently has 
the highest rates of resistance (ceftazidime) in general 
practice (GP) patients, hospitalized patients and those 
within the ICU (Figure 3; personal communication 
from the Paul Ehrlich Society, B. Wiedermann). 
Resistance development may be particularly 
devastating in patients with serious infections, e.g. 
neutropenic and immunocompromized patients, 
especially if prior antimicrobial therapy has been gven. 
Numerous cases of breakthrough bacteremia with 
multiply-resistant Entevobacter spp. in febnle neutropenic 
cancer patients and other patients receiving broad- 
spectrum cephalosporins have been reported [34]. The 
results of studies that have assessed the rates of resistance 
emerging among Enterobacteriaceae during or shortly 
after therapy with a number of cephalosporins are listed 
in Table 4 [S]. Resistance emerged in 1644% of treated 
2 5 r  
ICU 
U E. cloacae Klebsiella Proteus E. coli 
Figure 2 Relationship between crftazidime use and Figure 3 Ceftazidmie resistance among clinical isolates in 
susceptibility of Entevobacter cloacae to ceftazidime [2]. With 
permission of Diagn Microbiol Infect Dis. 
Germany (PEG 1990). 
Table 4 Rates of emergence of resistance in patients infected with Enterobacteriaceae organisms possessing inducible 
P-lactamases and treated with newer cephalosporins. Adapted from Sanders et al. with permission [ 8 ] .  
Total no. No.(%) of Frequency of clinical 
Organismd of patients patients with failure or relapseb 
emerging resistance 
Ceftriaxone Several 29 8 (28) 6 (21/75) 
Moxalactam Serratia marrescens 10 3 (30) 1 (10/33) 
1 (10/25) 
- 
Moxalactam Several 10 4 (40) 
Several Enterobacter species 9 4 (44) 
Several Several 44' 7 ( 1 6 ) C  3 (7/43)C 
aData summarized for entenc bacilli from four earlier publications (102 patients, not all of whom received a cephalosporin). 
bResults are expressed a9 the number of patients with therapy failure or relapse (percentage of total number of patientdpercentage of those 
?Includes P. aemginosa (24 of 49 strains in 44 patients). Only one of the resistant entenc bacilli cases received an extended spectrum p-lactam. 
with emerging redstance). Minus signs indicate that no data were provided. 
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patients (highest among Enterobacter spp.), with a mean 
rate of 25%. The rates were generally consistent among 
the various drugs examined. A more comprehensive 
review by Fish et al. documented a lower rate of 
emerging resistance (7.7-10.1%) for Citrobacter spp. 
and Entevobactev spp. [41]. Among patients in whom 
the emergence of resistance was detected, failure/relapse 
rates ranged from 25% to 75%, but emerging 
resistance did not predict clinical failure. The greatest 
risk of resistance and frequency of pathogen occurrence 
appear to occur with isolates ofE. cloacae and E. aerogenes, 
especially those cultured from respiratory tract sites 
(Tables 1 and 4). High morbidity and mortality cases 
were also associated with bone and joint infections 
and in patients with neutropenia and cystic fibrosis [9]. 
In one investigation, 15 of 16 isolates of Enterobacter 
spp. from neutropenic patients were resistant to 
extended-spectrum cephalosporins. In contrast, only 
12 of 35 isolates from non-neutropenic patients were 
resistant (p < 0.05) [34]. The neutropenic patients had 
received more 0-lactam therapy than the non- 
neutropenic patients. The authors concluded that 
prior 0-lactam exposure may predispose neutropenic 
patients to develop resistant Enterobacter bacteremia. 
Other  studies have described patients where 
cephalosporin-resistant Gram-negative bacteria have 
emerged during treatment, resulting in life-threatening 
secondary infections [8,31,33]. A total of 18 patients 
who were infected initially with susceptible organisms 
exhibited emergence of resistant strains during 
adrmnistration of cefmaxone, cefotaxime or ceftazidime, 
some despite combination therapy with aminoglycosides 
1331. Resistant strains of E .  cloacae, S. marcescens, 
K .  oxytora, P.  aeruginosa and C. jeund i i  emerged, 
probably by the selection of stably derepressed mutants, 
after 9 days of treatment. Thus, the selection of resistant 
bacteria may have serious clinical consequelices in 
patients with risk factors, such as impaired host-defence 
mechanisms, as the selection of resistance is associated 
with a significant rate of therapy failure and relapse. 
Risk of AmpC induction 
The extent of AmpC induction is dependent upon 
both the P-lactam-inducing agent and the inducer 
concentration [9,42-451. At sub-MIC concentrations, 
cefoxitin, long regarded as a potent inducing agent, 
has been shown to induce AmpC by 100- to 600-fold 
in strains of E. cloacae, C.freundii, P. stuartii, S .  marcescens, 
M .  morganii and P. aeruginosa [44]. However, the 
carbapenems, imipenem and meropenem, may prove 
to be at least as potent as cefoxitin as inducing agents 
for AmpC in C. freundii [9]. 
A consensus of published reports ranks the AmpC 
inducing potential for p-lactam classes [42-45). On 
this basis, carbapenems and cepliamycins are the most 
potent inducing agents (Table 5), followed by penicillins 
and the older cephalosporins. The fourth-generation 
cephalosporins, cefpirome and cefepime, have a lower 
risk of inducing AmpC than the P-lactamase inhibitor, 
clavulanic acid. Induction itself, however, does not 
imply a clinical risk, since the greatest inducers produce 
increased amounts of enzyme without a significant 
effect on the initial MIC (i.e. rapid bactericidal action 
beconies manifest before induction of the enzyme has 
been efficiently produced). 
Risk of AmpC selection 
Some 0-lactam antimicrobials arc more likely than others 
to select mutant subpopulations of resistant organisms 
and their widespread use in the hospital environment 
has resulted in the emergence of clinically iniportant 
endemic bacterial resistances [46]. These selection 
potential differences in individual inducible strains 
that cause infection (susceptible by reference test) 
remains unclear. 
The frequency of stably derepressed AmpC mutants 
in a bacterial population can be as high as 10-5 [4]. 
Such mutants have serious clinical implicatioiis and arc 
isolated in approximately 20% of infections involving 
ArnpC-producing strains during selective therapy with 
broad-spectrum 0-lactams [4]. Factors favoring thc 
Table 5 Induction potential at  concentrations below MIC (consensus from thc reported literature [42-45]) 
Induction Potential Rank 
Highest carbapcnems and cepliamycins 
aminopenicillins 
carhoxy-p enicillins 
ureidopenicillins 
older cephalosporins ( l T t ,  3"d and 3'") 
clavulanic acid 
newer ccphalosporiiis ( 4 ' 1 )  
sulphone? 
Lowest rrioriobactanis 
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occurrence and selection of such mutants include high 
bacterial inoculum at the infection site, bacterial species 
and strain involved. 
In an in vitro investigation of resistance development 
to third- and fourth-generation cephalosporins in 10 
strains of E.  cloacae, full resistance to ceftriaxone and 
ceftazidime occurred in at least half of the strains 
within 1-3 days of passage (Figure 4) [46]. This resistance 
development was associated with greatly enhanced 
AmpC production, but had only a modest effect upon 
outer-membrane protein profile as a resistance 
mechanism. In contrast, at least five passages were 
required before the majority of strains acquired resistance 
to fourth-generation cephalosporins. Resistance to the 
fourth-generation cephalosporins was associated with 
changes in the outer membrane proteins, but involved 
little alteration of AmpC expression. The latter results 
suggest that at least two genetic mutations, altered 
permeability and high Km, may be necessary to achieve 
resistance to newer zwittenonic cephalosporins. 
The  dramatic impact of  inducible AmpC 
P-lactamase-producing strains upon p-lactam 
susceptibility and clinical outcome makes it essential 
that clinical microbiology laboratories can identifj 
such strains reliably. The primary difficulties caused by 
Gram-negative pathogens with inducible p-lactamases 
stem from their apparent susceptibility, when tested 
against third-generation cephalosporins, in routine in 
r 
( 9 1 l O H  “ (811 0) 
128 
0 1 2 3 4 5 6 7 8  
Day of serial passage 
Figure 4 Median MICs for 10 E. cloacae strains during 
7-day serial passage with a cephalosporin. The median MIC 
represents the sixth MIC observation when the MICs for the 
10 strains on each day of testing are listed from the lowest 
to the highest value. The values in parentheses are the number 
of strains among the 10 strains tested for which the MIC was 
in the resistant range (2 32 mg/L) for the 7-day serial passage. 
* cekriaxone; 0 ceftazidime; 0 ceEpirome; 0 cefepime. 
The upper and lower broken lines in the figure are cut-offs 
for resistance and susceptibihty (NCCLS criteria), respectively. 
With permission of Am Soc Microbiol J Div [46]. 
vitro tests. However, accurate bacterial identification 
should be sufficient to raise the possibility of selecting 
derepressed AmpC mutants. Identification of the ‘at 
risk’ species is well within the specifications of most 
commonly used commercial kits (Vitek, MicroScan, 
Sensident, Micronaut, API, etc.). Information provided 
by computerized ‘Expert Systems’ for the interpretation 
of antimicrobial susceptibility testing, frequently 
coupled with the above cited commercial diagnostic 
systems, may also be useful. As confirmation, 
standardized susceptibility tests can accurately determine 
p-lactam susceptibility for the selected derepressed 
mutants without the need for elaborate or time- 
consuming induction or other non-standardized tests 
[42]. In a survey of over 8,500 strains conducted by 43 
laboratories in the USA, the observed rates (i.e. local 
center results) for ceftazidime resistance in E.  cloacae 
(28.4%) and C. fretrndii (31.0%) [3] were very similar 
to rates obtained (29.8% and 33.2%, respectively) by 
reference methods in the monitoring laboratory 1471. 
SIGNIFICANCE OF INDUCIBLE AND STABLY 
DEREPRESSED RESISTANCE 
Induction potential does not necessarily translate to 
reduced eficacy in either the laboratory or clinical 
situation [48]. Confounding variables, such as the 
presence of multiple resistance mechanisms, outer 
membrane penetration, PBP f in i ty ,  enzyme inhibition 
by the inducer and, most importantly, the p-lactamase 
stability of the inducer, can affect the periplasmic 
concentration of the p-lactam and hence bactericidal 
activity. Some compounds both strongly induce and 
are hydrolyzed by chromosomally-mediated enzymes 
of Gram-negative bacteria (e.g. the aminopenicillins 
and the cephamycins for E. cloacae). Other compounds 
(e.g. piperacillin and other cephalosporins), although 
poor inducers, are labile so that greatly increased 
MICs are observed, despite relatively modest levels of 
AmpC induction. In contrast, the high AmpC-inducing 
potential of the carbapenems does not compromize 
their efficacy due to high bacterial membrane 
penetration and relative P-lactamase stability. The 
fourth-generation cephalosporins also combine high 
penetration rates and P-lactamase stability with low 
induction potential [49]. 
ROLE OF NEW CEPHALOSPORINS IN THERAPY 
In common with third-generation cephalosporins, the 
fourth-generation cephalosporim have an aminothazolyl 
(or amino thiadiazoly1)-methoximino group at the 
C-7 position of the cephem nucleus (Figure 5) [50]. 
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Figure 5 C-3’ quaternary ammonium cephems [50]. 
However, these newer cephalosporins possess a 
quaternary ammonium group at the C-3’ position which 
confers a considerable increase in potency and has led 
to these compounds being termed ‘fourth-generation’ 
cephalosporins. These C-3’ substitutions confer a 
more balanced antimicrobial spectrum compared to 
ceftazidime and maintain stability to, and low affinity 
for, clinically important P-lactamases. They also g v e  
these compounds the properties of a zwitterion which 
enhances outer membrane permeability. The principal 
candidates for inclusion in the group are listed in 
Table 6 and include cefpirome and cefepime. 
Both cefpirome and cefepime have been shown 
to penetrate the outer membrane of E. cloacae 
approximately 5- to 6-fold faster than cefotaxime. This, 
coupled with much lower affinity (high Km) for and 
higher stability towards the AmpC P-lactamase, results 
in higher periplasmic coiicentrations than those achieved 
by cefotaxime [Sl]. Consequently, MIC,, values of 
0.5-1 mg/L are routinely achieved against E.  cloacae, as 
opposed to > 32 mg/L for cefotaxime and ceftazidime 
[52]. Pooling of data from nine studies produced a 
median MIC,, value of 1 mg/L for cefpirome against 
E. cloacae, compared to 50 mg/L for ceftazidime [53]. 
Fourth-generation cephalosporins have also 
demonstrated excellent activity against Enterobacter spp. 
isolated from ICU [18] and other units [54]. In one 
study in ICU infections, cefpirome and imipenem 
were the most potent against ceftazidime-resistant 
isolates, with 94% and 97%, respectively, of strains 
susceptible [MI.  With the exception of cefpirome, 
there was significant cross-resistance among the 
cephalosporins tested. 
Fourth-generation cephalosporins generally 
Table 6 List of candidate ‘fourth-generation’ cephalosporins for human use [50] 
C-7, 2-amino-5-thiazolyl C-7, 5-amino-2-thiadiazolyl 
Cefpironie (HR-810) 
Cefepime @MY-28142) 
Cefoselis (FK-037) 
Cefclidm (E-1040) 
Cefozopran (SCE-2787) 
Cefluprenam (E-1077) 
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maintain good activity against ceftazidime-resistant 
(MIC > 16 mg/L) Enterobacteriaceae with inducible 
AmpC P-lactamases. In an international study of 
160 ceftazidime-resistant strains [55], 74% were 
inhibited by cefpirome at 5 8 mg/L (Table 7). An 
identical rate of cefpirome susceptibility was noted 
in a five-nation survey (Table 7; Australia, France, 
Germany, Italy and UK) and in the USA [55]. In 
another 1 1-nation study of ceftazidime-resistant 
Enterobacteriaceae, > 80% of strains were inhibited 
by cefepime (5 8 mg/L), with the exception of some 
strains from Brazil (48%) and Italy (55%). Overall, 
cefpiroine and cefepime display similar activities against 
Enterobacteriaceae which produce inducible AmpC 
P-lactamases, while cefocelis (FK 037) appeared 
slightly less active [57,58]. 
As yet, there are limited published clinical studies 
to assess the efficacy of fourth-generation cephalosporins 
against serious Entevobacter infections and especially 
against strains resistant to thlrd-generation cephalosporins 
[59-611. However, early indications are promising [61]. 
From pooled comparative clinical trials using cefepime 
(2,487 patient cases), 17 infections with Enterobacter 
spp. caused by organisms tested as susceptible to 
cefepime, but resistant to ceftazidime were observed 
and Infection, Volume 3 Supplement 1 ,  Apr i l  1997 
1611. Cefepime therapy resulted in clinical cure in all 
patients and an 88.2% bacteriologcal eradication rate. 
Also, no emergence of resistance was noted. In a study 
of 276 hospitalized patients with severe infections, 
three were attributable to E .  cloacae, and were eradicated 
following treatment with cefpirome at 1 or 2 g bid 
(Table 8) [59]. In another study involving less serious 
infections [60], ceftazidime produced bacterial 
eradication in 70% of patients, whereas cefpirome at 
1 g bid achieved 100% eradication (Table 8). In a 
Scandinavian study, cefpirome dosed at 1 g bid was 
found to be at least as effective as ceftazidime 1 g tid 
in eradicating Citrobacter and Entevobacter spp. from the 
urinary and respiratory tracts [62]. 
Another recent multicenter study compared 
the efficacy and safety of cefpirome and ceftazidime 
in the empiric treatment of  nosocomial and 
community-acquired pneumonia in the ICU [63]. A 
satisfactory bacteriological response was achieved in 
73% and 64% of patients receiving cefpirome (2 g bid) 
and ceftazidime (2 g tid), respectively, for infections 
caused by Enterobacter spp. Similarly, cefepime has 
demonstrated favourable results compared to 
ceftazidime in the treatment of infections caused by 
Enterobacteriaceae [64]. 
Table 7 Distribution of Gram-negative ceftazidime-resistant (MIC > 16 mg/L) Enterobacteriaceae strains by cefpirorne 
MICsd 
Strains with following cefpirome MIC (mg/L) 
Organism No. of strains 5 0.5 1 2 4 8 16 > 16 
Citro bacter spp . 23 6 0 6 3 5 1 2 
E. cloacae 99 15 14 12 17 14 5 22 
Enterobacter spp.' 19 12 1 1 3 1 1 0 
H .  aluei 7 2 0 1 1 0 0 3 
M .  moyanii 6 2 1 0 0 0 1 2 
P. stuartii 1 0 0 1 0 0 0 0 
S. marcescens 5 0 0 0 0 1 0 4 
Totald 160 37 16 21 24 21 8 33 
%Modified from 155,561 for strains from the USA, Australia, France, Germany, Italy and the UK. 
bIncludes Citrobacterfreundii (20 strains) and Citrobactev spp. (three strains, not speciated). 
CIncludes Enterobacter aeroxenes (1 5 strains) and Enterobactrr spp. (four strains, not speciatcd). 
d74.4% of tested strains were susceptible (2 8 mg/L). 
Table 8 Eradication rates for cefpirome used against infections caused by Enterobarter spp. [59,60] 
No. eradicated/No. treated 
Study (year) 1 g bid 2 g bid All cases 
Carbon et al. (1992) 2/2 1/1 3/3 
Study group (1992) 15/15a - 15/15a 
acornparator (ceftazidime) eradication rate = 70%. 
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ROLE OF ALTERNATIVE AGENTS 
A number of alternative agents are available for the 
treatment of serious Gram-negative infections, 
although these too have resistance problems. Indeed, 
strains resistant to third-generation cephalosporins 
show a higher rate of resistance to other antibiotics of 
unrelated classes, such as amikacin, gentamicin and 
ciprofloxacin [Privitera, personal communication] 
(Table 9). Amongst the p-lactam antimicrobials, the 
carbapenems (imipenem, meropenem) have the 
broadest antimicrobial spectrum. Imipenem readily 
enters the periplasmic space of Enterobacter spp. via a 
different poriii channel to that used by cephalosporins 
and inhibits the PBPs; it is also highly p-lactamase 
stable. However, clinical isolates of Enterobncter spp. 
and P.  aeruginosa that are resistant to imipenem have 
been isolated recently 1651. In the USA, resistance to 
imipenem among Enterobacteriaceae (Protens spp.) 
varied from 1-46%, depending on the species 1661. 
However, these figures also include false-positive 
results from some commercial systems (Vitek), 
emphasizing the need for in vitro monitoring methods 
using reference standards [3,66]. 
Aminoglycoside resistance continues to be a 
problem in the treatment of nosocornial infections. 
Modest increases in aminoglycoside resistance over 
time have occurred, even with acceptable infection 
control practices and therapeutic drug level 
monitoring. Current resistance problems with 
aminoglycosides include resistance mediated by 
reduced drug uptake in Enterobacteriaceae and 
Pseudomorias spp. and plasmid-mediated modifying 
enzymes (often multiple) in Enterobacteriaceae, 
Pseudomorias spp. and Gram-positive species. 
Most parenteral fluoroquinolones are characterized 
by their broad-spectrum activity, although recent years 
have seen the emergence of resistant strains. Current 
resistance problems associated with the fluoroquinolones 
include resistance aniong methicillin-resistant 
Staphylococcus aurens (MRSA). Future problems which 
may become more common include resistance among 
Pseudomonas spp. and Enterobacteriaceae attributed 
to altered DNA topoisomerases or modified drug 
permeability. Ciprofloxacin resistance has been 
reported in C. fietrndii (9.9%), S. marcpscens (6.8%) and 
P. aeruginora (14.9%) in the U S 4  in 1993-1994 [3,66] 
and in other countries 1641. 
CON CLU SI 0 NS 
Emerging resistance among Enterobacteriaceae will 
continue to compromize therapy with existing third- 
generation cephalosporins. The  fourth-generation 
cephalosporins penetrate the bacterial outer-membrane 
more rapidly, have greater p-lactamase stability and, 
therefore, have a broader antimicrobial spectrum and 
higher intrinsic activity than third-generation agents. 
These features will sustain the class therapeutic ef'iicacy 
against strains involved in serious infections in 
hospitalized patients. 
Fourth-generation cephalosporins are active against 
the majority of P.  aeruginosa and could be used as an 
alternative to ceftazidime as the cephalosporin of choice 
in combination regimens for such infections. Cef@rome 
and some other fourth-generation compounds have 
potent activity against oxacdin-susceptible staphylococci 
[65] and the majority of penicillin and multidrug- 
resistant streptococci [67,68]. Despite the improved 
activity and spectrum of cefpironie, it is likely that 
co-drugs will continue to be necessary for maximal 
empiric therapy of serious nosoconiial infections 
including bacteremia, pneumonia and mixed anaerobic 
infections such as those in surgery patients. 
Other factors, for example less frequent dosing, 
safety, cost and favorable interactions with other drugs 
(i.e. synergistic killing) will also be important factors 
in selecting alternative agents to complement or replace 
third-generation cephalosporins or other p-lactanis in 
the treatment of infections caused by strains producing 
Bush Group 1 enzymes (inducible or derepressed 
expression). 
Table 9 Association of resistance to other  antimicrobial classes among 252 strains of Enterobacteriaceae liaving rcsistance to 
third-generation cephalosporins (Italy, 1995) 
Organism (No. tested) "/o Resistances 
Amikacin Gentamicin Ciprofloxacin 
C.  ficwdii  
E .  aerqqerzcs 
E .  cloacac 
S .  rnarcescews 
13.6 
24.3 
3.1 
13.9 
31.8 
15.5 
29.0 
63.9 
28.6 
48.5 
25.6 
55.2 
5uyccptibility interprrtation criteria published by the NCCLS (1995) 
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DISCUSSION 
Prof. B. Weidemann: There may be differences in 
the induction potential within the cephamycin group 
of cephalosporins and possibly among the carbapenems, 
for instance, imipenem has a greater induction potential 
than meropenem. 
Prof. F. Baquero: It remains unclear whether 
differences in the induction potential between strains 
of a particular species are important. For cef’pirome, 
the low induction can be partially explained by the 
rapid bactericidal activity, as both cefoxitin and 
cefpirome are equally effective against the cell wall. 
The inducer is produced at the same rate for both 
cephalosporins, therefore, the observed differences are 
related to the relative speeds of killing; rather than 
differences in induction potential. 
Prof. B. Wiedemann: Differences in the induction 
potential of the drugs are related to binding to PBP 5. 
The stronger the binding to PBP 5 ,  then the more 
intense the induction. 
Prof. K. Klugman: The increasing worldwide 
importance of the extended-spectrum P-lactamases 
(ESBLs), should not be overlooked, particularly 
regarding the impact on MIC values. 
Prof. R. Jones: Yes I agree, the overall pattern of 
emerging resistance in E.  coli, or Klebsiella spp. is going 
to mimic the pattern among stably-derepressed 
P-lactamase-producing Enterobacter or Citrobacter to the 
clinical microbiologist. Would Dr Bauemfeind address 
this issue? 
Dr. A. Bauernfeind: To be more specific, the 
incidence of AmpC genes on plasmids is increasing 
world-wide. However, one advantage of the fourth- 
generation cephalosporins is that they retain good in 
vitro activity against arnpC plasmid containing strains. 
Prof. F. Baquero: The activity against plasmid 
mediated ampC producing Enterobacteriaceae is a 
potential advantage for the fourth-generation 
cephalosporins. 
Prof. R. Jones: The number of strains with ESBL 
phenotypes is becoming alarmingly high in the USA. 
Dr Pfaller, do you have any comment on this? 
Dr. M. Pfaller: Recent data demonstrate that 2 40% 
of Klebsiella spp. in individual institutions are ESBL- 
producing strains. Not all these strains are the result of 
an outbreak of a single clone, and the percentage vanes 
from one institution to another and between strains in 
the same medical center. There is considerable 
variation in the incidence of ESBLs and the incidence 
should be closely monitored. 
Prof. R. Jones: In hospitals with a hlgh incidence of 
ESBL phenotypes, approximately 50% of strains are 
cefoxitin-resistant, often carrying multiple resistance 
phenotypes. This appears to be due to mobilization of 
the arnpC gene into K. pneumoniae. Approximately 17% 
of current bacteremias in a large hospital sample (60 
medical centers) in the USA, due to K. pneumoniae, are 
ESBL or ampC phenotypes. 
Prof. F. Baquero: In the study by Dr. E. Sanders, 
the emergence of ampC mutants were not detected 
following a 1 g bid dose of cefepime. In an analysis of the 
ceftazidime-resistant strains a trimodal MIC mstribution 
was observed for cefepime; one peak was at 0.5 mg/L, 
one at about 4 mg/L and one at 2 8 mg/L. These strains 
may also exhibit increased MIC values the carbapenems. 
Prof. R. Jones: Examination of the susceptibility 
testing data demonstrates that the usual cefepime MIC 
was in the ‘first mode’ (previously mentioned). All the 
fourth-generation cephalosporins tested against these 
ceftazidime-resistant strains exhibit a trimodal effect, 
although there is variation of the MIC values of 
particular agents. 
Prof. J. Turnidge: The main problem with the 
emergence of resistance is with Enterobacter cloacae, which 
is the most prevalent of pathogens and also seems to 
have the highest propensity for the development of 
resistance. 
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